Solid Tumor Clinical Trials in Los Angeles, California

105 recruitingLos Angeles, California

Showing 120 of 105 trials

Recruiting
Phase 1Phase 2

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid Tumors
Novartis Pharmaceuticals280 enrolled33 locationsNCT06726148
Recruiting
Phase 1Phase 2

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Breast CancerSolid Tumors, Adult
Eli Lilly and Company880 enrolled66 locationsNCT05768139
Recruiting
Phase 1

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

Ovarian CancerOvarian CarcinomaAdvanced Solid Tumor+8 more
NiKang Therapeutics, Inc.150 enrolled19 locationsNCT06586957
Recruiting
Phase 1

Study of INCB123667 in Subjects With Advanced Solid Tumors

Solid Tumors
Incyte Corporation604 enrolled42 locationsNCT05238922
Recruiting
Phase 1

Study of XB010 in Subjects With Solid Tumors

Locally Advanced or Metastatic Solid TumorsNSCLC (Non-small Cell Lung Cancer)Esophageal Squamous Cell Cancer+1 more
Exelixis396 enrolled19 locationsNCT06545331
Recruiting
Phase 1

A Phase 1/1b Study of IAM1363 in HER2 Cancers

HER2-positive Breast CancerHER2 + Breast CancerHER2 Mutation-Related Tumors+10 more
Iambic Therapeutics, Inc383 enrolled48 locationsNCT06253871
Recruiting
Phase 1Phase 2

Gene Therapy for HER-Positive Cancer (SENTRY-HER2)

HER2 Expressing Solid Tumors
Vironexis Biotherapeutics Inc.27 enrolled4 locationsNCT07192432
Recruiting
Phase 1Phase 2

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Ovarian CancerEndometrial CancerProstate Cancer+5 more
PMV Pharmaceuticals, Inc300 enrolled76 locationsNCT04585750
Recruiting
Phase 1

A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors

Breast CancerEndometrial CancerAdvanced Solid Tumor+2 more
Alterome Therapeutics, Inc.110 enrolled51 locationsNCT06533059
Recruiting
Phase 1Phase 2

SMP-3124LP in Adults With Advanced Solid Tumors

Solid Tumor
Sumitomo Pharma America, Inc.120 enrolled10 locationsNCT06526819
Recruiting
Phase 2

A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

Recurrent or Metastatic Solid Tumors
Daiichi Sankyo520 enrolled119 locationsNCT06330064
Recruiting
Phase 1

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

Breast CancerOvarian CancerEndometrial Cancer+2 more
IDEAYA Biosciences216 enrolled27 locationsNCT05787587
Recruiting
Phase 1

A Study of MGC026 in Participants With Advanced Solid Tumors

Advanced Solid TumorSquamous Cell Carcinoma of Head and NeckMetastatic Cancer+1 more
MacroGenics250 enrolled12 locationsNCT06242470
Recruiting
Phase 1Phase 2

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

HER2-positive Advanced Solid Tumor
DualityBio Inc.796 enrolled102 locationsNCT05150691
Recruiting
Phase 2

A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors

Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal CancerPart 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
AstraZeneca468 enrolled123 locationsNCT04482309
Recruiting
Phase 1Phase 2

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

Advanced Solid TumorHigh Grade Serous Adenocarcinoma of OvarySquamous Non-small-cell Lung Cancer
Volastra Therapeutics, Inc.200 enrolled14 locationsNCT05902988
Recruiting
Phase 1Phase 2

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

Advanced Solid Tumors
LigaChem Biosciences, Inc.300 enrolled8 locationsNCT05941507
Recruiting
Phase 1Phase 2

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

Solid Tumor, Adult
A2 Biotherapeutics Inc.240 enrolled10 locationsNCT06682793
Recruiting
Phase 1

First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer

Breast CancerAdvanced CancerAdvanced Solid Tumors+1 more
OnKure, Inc.200 enrolled34 locationsNCT06239467
Recruiting
Phase 1Phase 2

Study of DF1001 in Patients with Advanced Solid Tumors

Solid Tumor, Adult
Dragonfly Therapeutics378 enrolled52 locationsNCT04143711